See every side of every news story

Published 2 days ago • loading... • Updated 2 days ago

Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025

Antengene presented preclinical data of ATG-201 at the 2025 American College of Rheumatology Annual Meeting.
ATG-201 showed stronger B cell depletion and lower cytokine release compared to benchmark T-cell engagers.
ATG-201 effectively induces CD19-dependent CD3 binding, leading to B cell depletion and disease suppression.
Antengene plans to advance ATG-201 into clinical development in Q4 2025.

Insights by Ground AI

69 Articles

69 Articles

The Manila Times

PR Newswire

Charleston Gazette-Mail

Watauga Democrat

Rockdale Citizen & Newton Citizen

NNY360

Local 3 News

TBNweekly

Henry Herald

The Herald-Dispatch

The Northern Virginia Daily

Brattleboro Reformer

The Courier Express

Madison Courier

Bennington Banner

The Berkshire Eagle

Mt. Airy News

Rutland Herald

The Progress

Tullahoma News

blackbeltnewsnetwork.com

waynecountynews.com

The Coal Valley News

http://www.wfxg.com

williamsondailynews.com

The Logan Banner

Suncoast News

newsontheneck.com

carolinapanorama.com

Laotian Times

The Westerly Sun

The Times-News

The AI Journal

mainstreetnews.com

MyHorryNews.com

The Daily News - Jacksonville, NC

Finger Lakes Times

Williamson Herald

Herald Chronicle

coastaltvnews.com

The Daily Press

Biltmore Beacon

Saint Albans Messenger

blockislandtimes.com

The Caswell Messenger

Essex Reporter

News of Orange

theritchiegazette.com

Rappahannock News

Prince William Times

willistonobserver.com

Westminster Cable Network

decaturdailydemocrat.com

Observer News Enterprise

Loudoun Now

Daytona Times

The Kane Republican

Courier Journal

The Erwin Record

SRI News

The Inquirer and Mirror

delmarvasportsnetwork.com

The Tomahawk

www.Arundel.News

miltontimes.com

Lincoln Times News

mountaineagle.com

grundycountyherald.com

+68 Reposted by 68 other sources

Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025

SHANGHAI and HONG KONG, Oct. 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources69

Leaning Left4Leaning Right5Center21Last Updated1 day agoBias Distribution

70% Center

Bias Distribution

70% of the sources are Center

70% Center

+16

Untracked bias

+30

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States 2 days ago on Monday, October 27, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics